Latest Industry Projects

Vernalis plc enters into research collaboration with Asahi Kasei Pharma

projects

Vernalis plc announced today that it has entered into a drug discovery collaboration with Asahi Kasei Pharma (AKP), utilizing Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid arthritis and other autoimmune diseases. The financial terms of this collaboration are not disclosed. Ian Garland, CEO of Vernalis, commented: "We are delighted to be selected by AKP to work with them on this target. This further endorses our market leading fragment and structure-based drug discovery platform and validates our strategy to fund our research activities through collaborations. We look forward to a successful collaboration with Asahi Kasei Pharma." Osamu Matsuzaki, General Manager of Pharmaceuticals Research Center of AKP said "We have been impressed by the extensive expertise of Vernalis on SBDD and FBDD technologies. This collaboration greatly enhances AKP's efforts on the development of novel treatment of autoimmune diseases.” http://www.vernalis.com/media-centre/latest-releases/662-vernalis-plc-enters-into-research-collaboration-with-asahi-kasei-pharma Project Name Vernalis plc Location England Commence NA Completion NA Estimated Investment NA Capacity NA Key Players Vernalis plc

Other Projects